L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.4 NOK 3.45% Market Closed
Market Cap: 368.6m NOK

Intrinsic Value

LYTIX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one LYTIX stock under the Base Case scenario is 2.52 NOK. Compared to the current market price of 5.4 NOK, Lytix Biopharma AS is Overvalued by 53%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LYTIX Intrinsic Value
2.52 NOK
Overvaluation 53%
Intrinsic Value
Price
L
Worst Case
Base Case
Best Case

Valuation History
Lytix Biopharma AS

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
LYTIX
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for LYTIX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Lytix Biopharma AS
OSE:LYTIX
NO
Biotechnology
Market Cap
368.1m NOK
IPO
Jun 14, 2021
NO
Biotechnology
Market Cap
368.1m NOK
IPO
Jun 14, 2021
Price
krfalse
EPS
krfalse
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Lytix Biopharma AS
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lytix Biopharma AS

Current Assets 143.9m
Cash & Short-Term Investments 130.8m
Receivables 13.1m
Non-Current Assets 2.6m
PP&E 2.6m
Efficiency

Free Cash Flow Analysis
Lytix Biopharma AS

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Lytix Biopharma AS

Revenue
11.1m NOK
Operating Expenses
-107m NOK
Operating Income
-95.9m NOK
Other Expenses
1.6m NOK
Net Income
-94.3m NOK
Fundamental Scores

LYTIX Profitability Score
Profitability Due Diligence

Lytix Biopharma AS's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Declining ROE
26/100
Profitability
Score

Lytix Biopharma AS's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

LYTIX Solvency Score
Solvency Due Diligence

Lytix Biopharma AS's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
70/100
Solvency
Score

Lytix Biopharma AS's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LYTIX Price Targets Summary
Lytix Biopharma AS

Wall Street analysts forecast LYTIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYTIX is 14.28 NOK with a low forecast of 14.14 NOK and a high forecast of 14.7 NOK.

Lowest
Price Target
14.14 NOK
162% Upside
Average
Price Target
14.28 NOK
164% Upside
Highest
Price Target
14.7 NOK
172% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Lytix Biopharma AS
does not pay dividends
Shareholder Yield

Current shareholder yield for LYTIX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest
What is the Intrinsic Value of one LYTIX stock?

The intrinsic value of one LYTIX stock under the Base Case scenario is 2.52 NOK.

Is LYTIX stock undervalued or overvalued?

Compared to the current market price of 5.4 NOK, Lytix Biopharma AS is Overvalued by 53%.

Back to Top